Clinical proof-of-concept has been achieved for TRL1068 in a planned interim analysis based on completion of the second of three escalating dose groups 75% of chronic PJI patients treated with a single dose of TRL1068 and standard antibiotics had a bacterial biofilm burden below 100…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.